Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update

Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Guallar-Garrido, Sandra, Julián, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025668/
https://www.ncbi.nlm.nih.gov/pubmed/32104666
http://dx.doi.org/10.2147/ITT.S202006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025668/
https://www.ncbi.nlm.nih.gov/pubmed/32104666
http://dx.doi.org/10.2147/ITT.S202006

Ejemplares similares